VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study (NCT06249555)

🧪 Interventions in This Study

• Vedolizumab (VDZ) (DRUG)
• Ustekinumab (UST) (DRUG)
• Risankizumab (RISA) (DRUG)
• Guselkumab (GUS) (DRUG)
• Mirikizumab (MIR) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• GI Alliance - Sun City — Sun City, Arizona
• Northwestern University — Evanston, Illinois
• University of Iowa — Iowa City, Iowa
• University Medical Center New Orleans — New Orleans, Louisiana
• Brigham and Women's Hospital — Chestnut Hill, Massachusetts
• University of North Carolina — Chapel Hill, North Carolina
• Cleveland Clinic Foundation — Cleveland, Ohio
• OR Clinic - East - GI — Portland, Oregon
• GI Alliance Research Fort Worth — Fort Worth, Texas
• GI Alliance Research Mansfield — Mansfield, Texas
• GI Alliance - Bellevue - Washington Gastroenterology — Bellevue, Washington
• University of Alberta — Edmonton, Alberta
• University of British Columbia — Vancouver, British Columbia
• GNRR Digestive Clinics and Research Center — Brampton, Ontario
• London Health Sciences Centre — London, Ontario
• Alimentiv — London, Ontario
• West GTA Research Inc. — Mississauga, Ontario
• Rajbir Rai Medicine Professional Corporation — Oakville, Ontario
• ABP Research Services Corp. — Oakville, Ontario
• The Ottawa Hospital — Ottawa, Ontario
• Scarborough Center for Inflammatory Bowel Disease — Scarborough Village, Ontario
• Toronto Immune & Digestive Health Institute Inc. — Toronto, Ontario
• McMaster University Medical Center — Hamilton, Ontatrio
• Montreal General Hospital — Montreal, Quebec

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn's Disease

• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
• Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
• Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts

Explore by condition: All Crohn's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.